研究单位：[1]Ruijin Hospital[2]Affiliated Hospital of Hebei University,Baoding,China[3]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China[4]Xiangya Hospital Central South University,Changsha,China[5]Heping Hospital Affiliated to Changzhi Medical College,Changzhi,China[6]Sichuan Cancer Hospital & Institute,Chengdu,China[7]Sichuan Provincial People's Hospital,Chengdu,China[8]The Affiliated Hospital of Guizhou Medical University,Guiyang,China[9]Hainan Cancer Hospital,Haikou,China[10]Cancer Hospital of the University of Chinese Academy of Sciences,Hangzhou,China[11]The Second Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,China[12]Hefei Cancer Hospital, Chinese Academy of Sciences,Hefei,China[13]Lanzhou University Second Hospital,Lanzhou,China[14]Changhai Hospital,Shanghai,China[15]Ruijin Hospital, Shanghai Jiaotong University School of Medicine,Shanghai,China[16]Liaoning Cancer Hospita & Institute,Shenyang,China[17]The Fourth Hospital of Hebei Medical University,Shijiazhuang,China[18]Jilin Guowen Hospital,Siping,China[19]Shanxi Provincial Cancer Hospital,Taiyuan,China[20]First Affiliated Hospital of Xi'an Jiaotong University,Xian,China[21]Tangdu Hospital,Xian,China[22]Yantai Yuhuangding Hospital,Yantai,China[23]Henan Provincial Cancer Hospital,Zhengzhou,China[24]Affiliated Hospital of Jiangsu University,Zhenjiang,China
研究目的：
The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
